Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
Navidea Biopharmaceuticals (NAVB) announced its Q1 2021 financial results, reporting total net revenues of $124,000, down from $156,000 in Q1 2020. The net loss for the quarter was $3 million, or $0.11 per share. R&D expenses increased to $1.2 million, driven by higher development costs. Despite these challenges, the company is advancing its clinical trials, including NAV3-32 in rheumatoid arthritis, while engaging positively with the FDA. Notably, it secured a $5 million investment through a stock purchase agreement.
- Continued dialogue with the FDA for NAV3-31 and preparation for Phase 3 study.
- Initiated patient enrollment for NAV3-32 in the U.S. and UK.
- Opened new trial sites enhancing clinical study progression.
- Received patent allowance for diagnosis and treatment of viral infections.
- Completed a significant funding round with $5 million raised from Series E Preferred Stock.
- Total net revenues decreased by 20% compared to Q1 2020.
- Net loss increased to $3 million from $2.7 million in Q1 2020.
- R&D expenses rose by 20%, indicating higher operational costs.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended March 31, 2021.
“We are continuing a positive dialogue with the FDA and are moving as quickly as we can to fully document all the data from Arm 3 of NAV3-31,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. “We are also excited to begin patient enrollment for NAV3-32 both here in the U.S. and in the UK.”
First Quarter 2021 Highlights and Subsequent Events
- Submitted a formal Type B Meeting Request to the U.S. Food and Drug Administration (“FDA”). The FDA granted the Type B Meeting and reviewed the formal briefing documents Navidea submitted containing results from the NAV3-31 Phase 2B study and the proposed Phase 3 design and protocol. Following the feedback received from the FDA at the end of March 2021, the Company continues to work toward completing the analysis of the full trial dataset in preparation for the standard End of Phase 2 Type B meeting and in preparation for the Phase 3 study.
- Achieved last patient, last visit in the Company’s NAV3-31 Phase 2B study. Study closeout and data analysis are ongoing.
- Opened the first US site, Northwestern University, as well as the primary UK site, Queen Mary University of London, for enrollment in the Company’s NAV3-32 Phase 2B trial comparing Tc99m tilmanocept imaging to histopathology of joints of patients with active rheumatoid arthritis (“RA”).
- Opened the NAV3-35 trial to establish a normative database of healthy controls for Tc99m tilmanocept imaging in rheumatoid arthritis.
- Continued enrollment in the Investigator-Initiated Phase 2 trial being run at the Massachusetts General Hospital evaluating Tc99m tilmanocept uptake in atherosclerotic plaques of HIV-infected individuals.
- Received a notice of allowance from the United States Patent and Trademark Office for the patent application: “Compounds and methods for diagnosis and treatment of viral infections” (U.S. Patent Application 15/729,635).
- Announced that the results from the Company’s preclinical studies of its targeted cancer immunotherapeutic agent will be presented as a poster at the New York Academy of Science’s (“NYAS”) Frontiers in Cancer Immunotherapy Symposium 2021. The poster is titled, “Targeted Delivery of Doxorubicin (DOX) to Tumor Associated Macrophages (TAMs) Beneficially Alters the Tumor Immune Microenvironment and Synergizes the Activity of Anti-CTLA4.”
-
Entered into a Stock Purchase Agreement and Letter of Investment Intent with an existing investor, pursuant to which the Company issued to the investor 50,000 shares of newly-designated Series E Redeemable Convertible Preferred Stock (the “Series E Preferred Stock”) for an aggregate purchase price of
$5.0 million . The Series E Preferred Stock is convertible into a maximum of 2,173,913 shares of Common Stock. - Appointed Amit Bhalla to the Company’s Board of Directors. Mr. Bhalla brings a wealth of financial experience to the board.
Michael Rosol, Ph.D., Chief Medical Officer for Navidea, said, “The clinical research team is working diligently to advance the technology in key disease areas, with an emphasis on our RA program. We are completing the analysis of the full dataset from the NAV3-31 Phase 2B trial as well as planning for the Phase 3 trial. We continue to prepare for initiation of this trial and have opened up key sites for enrollment into the NAV3-32 Phase 2B trial comparing tilmanocept imaging to synovial tissue biopsy samples of RA patients. Concurrent with all of this, we continue to make exciting progress in our therapeutics pipeline, some of which will be presented this month at the NYAS conference, and we expect to continue to advance these towards the clinic.”
Financial Results
-
Total net revenues for the first quarter of 2021 were
$124,000 , compared to$156,000 for the same period in 2020. The decrease was primarily due to decreased grant revenue related to Small Business Innovation Research grants from the National Institutes of Health supporting Manocept™ development, offset by the partial recovery in the first quarter of 2021 of debts previously written off in 2015. -
Research and development expenses for the first quarter of 2021 were
$1.2 million , compared to$999,000 in the same period in 2020. The increase was primarily due to net increases in drug project expenses, including increased Manocept diagnostic and therapeutic development costs and increased Tc99m development costs, offset by decreased employee compensation. -
Selling, general and administrative expenses for the first quarter of 2021 were
$2.2 million , compared to$1.8 million in the same period in 2020. The net increase was primarily due to increased legal and professional services, insurance, investor relations services, and employee compensation, offset by decreased franchise taxes. -
Navidea’s net loss attributable to common stockholders for the first quarter of 2021 was
$3.0 million , or$0.11 per share, compared to$2.7 million , or$0.13 per share, for the same period in 2020. -
Navidea ended the first quarter of 2021 with
$7.5 million in cash and cash equivalents.
Conference Call Details
Investors and the public are invited to dial into the earnings call through the information listed below, or participate via the audio webcast on the company website. Participants who would like to ask questions during the question and answer session will be prompted by the moderator, who will provide instructions.
Event: |
Q1 2021 Earnings and Business Update Conference Call |
|
Date: |
Tuesday, May 11, 2021 |
|
Time: |
5:00 p.m. (EDT) |
|
U.S. & Canada Dial-in: |
877-407-0312 |
|
International Dial-in: |
|
+1 201-389-0899 |
Conference ID: |
13718969 |
|
Webcast Link: |
|
A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to comply with the NYSE American continued listing standards; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
| NAVIDEA BIOPHARMACEUTICALS, INC. | |||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||
| March 31, | December 31, | ||||||||
|
2021 |
|
2020 |
||||||
| (unaudited) | |||||||||
| Assets: | |||||||||
| Cash and cash equivalents | $ |
7,507,319 |
$ |
2,670,495 |
|||||
| Other current assets |
|
1,320,720 |
|
3,857,833 |
|||||
| Non-current assets |
|
1,249,036 |
|
1,229,690 |
|||||
| Total assets | $ |
10,077,075 |
$ |
7,758,018 |
|||||
| Liabilities and stockholders' equity: | |||||||||
| Current liabilities | $ |
4,158,754 |
$ |
4,715,105 |
|||||
| Deferred revenue, non-current |
|
700,000 |
|
700,000 |
|||||
| Other liabilities |
|
209,439 |
|
296,006 |
|||||
| Total liabilities |
|
5,068,193 |
|
5,711,111 |
|||||
| Navidea stockholders' equity |
|
4,277,581 |
|
1,315,604 |
|||||
| Noncontrolling interest |
|
731,301 |
|
731,303 |
|||||
| Total stockholders' equity |
|
5,008,882 |
|
2,046,907 |
|||||
| Total liabilities and stockholders' equity | $ |
10,077,075 |
$ |
7,758,018 |
|||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||
| Three Months Ended | |||||||||||
| March 31, | March 31, | ||||||||||
|
2021 |
|
|
2020 |
|
||||||
| (unaudited) | (unaudited) | ||||||||||
| Revenue | $ |
123,737 |
|
$ |
156,272 |
|
|||||
| Cost of revenue |
|
- |
|
|
609 |
|
|||||
| Gross profit |
|
123,737 |
|
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What are the financial results of Navidea Biopharmaceuticals for Q1 2021?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Navidea reported net revenues of $124,000 and a net loss of $3 million, or $0.11 per share."
}
},
{
"@type": "Question",
"name": "How is Navidea progressing with its clinical trials?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Navidea is advancing its NAV3-32 trial for rheumatoid arthritis and is in positive discussions with the FDA regarding NAV3-31."
}
},
{
"@type": "Question",
"name": "What funding has Navidea secured recently?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Navidea raised $5 million through the issuance of Series E Redeemable Convertible Preferred Stock."
}
},
{
"@type": "Question",
"name": "What were Navidea's expenses in Q1 2021?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Research and development expenses were $1.2 million, while selling, general, and administrative expenses were $2.2 million."
}
},
{
"@type": "Question",
"name": "What is the significance of the FDA dialogue for Navidea?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The ongoing dialogue with the FDA is crucial for the progression of Navidea's clinical trials and future drug approvals."
}
}
]
}
FAQ
What are the financial results of Navidea Biopharmaceuticals for Q1 2021?
Navidea reported net revenues of $124,000 and a net loss of $3 million, or $0.11 per share.
How is Navidea progressing with its clinical trials?
Navidea is advancing its NAV3-32 trial for rheumatoid arthritis and is in positive discussions with the FDA regarding NAV3-31.
What funding has Navidea secured recently?
Navidea raised $5 million through the issuance of Series E Redeemable Convertible Preferred Stock.
What were Navidea's expenses in Q1 2021?
Research and development expenses were $1.2 million, while selling, general, and administrative expenses were $2.2 million.
What is the significance of the FDA dialogue for Navidea?
The ongoing dialogue with the FDA is crucial for the progression of Navidea's clinical trials and future drug approvals.
NAVIDEA BIOPHARMS INC
OTC:NAVBNAVB RankingsNAVB Latest NewsJul 3, 2024
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
Jun 20, 2024
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
NAVB Stock Data | |||||||